If women are discouraged from getting mammograms, as a U.S. government panel recently advised, some will die, but at least others will be spared the discomfort of getting mammograms. There isn't a similar upside to the following decision by Britain's socialized medical system, described by London's Daily Mail:
Liver cancer sufferers are being condemned to an early death by being denied a new drug on the Health Service, campaigners warn.
They criticised draft guidance that will effectively ban the drug sorafenib--which is routinely used in every other country where it is licensed.
Trials show the drug, which costs £36,000 [about $60,000] a year, can increase survival by around six months for patients who have run out of options.
The Government's rationing body, the National Institute for Health and Clinical Excellence (Nice) said the overall cost was "simply too high" to justify the 'benefit to patients'.
Buck up, liver cancer sufferers! "In Britain, the government itself runs the hospitals and employs the doctors," former Enron adviser Paul Krugman assures you. "We've all heard scare stories about how that works in practice; these stories are false."